Comments to FDA: Benzocaine

Share page:
Docket Number:
1981N-0033

CHPA appreciates the comments of FDA in the February 2006, feedback letter and understands that these comments are FDA’s best advice on designing a protocol to address the safety and efficacy of benzocaine. We have included a revised final protocol for your final review.

Related Posts

CHPA Statement on Valisure Citizen Petition